History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium

Albina N Minlikeeva; Jo L Freudenheim; Kevin H Eng; Rikki A Cannioto; Grace Friel; J Brian Szender; Brahm Segal; Kunle Odunsi; Paul Mayor; Brenda Diergaarde; Emese Zsiros; Linda E Kelemen; Martin Köbel; Helen Steed; Anna deFazio; Susan J Jordan; Peter A Fasching; Matthias W Beckmann; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Jenny Chang-Claude; Marc T Goodman; Thilo Dörk; Robert Edwards; Francesmary Modugno; Roberta B Ness; Keitaro Matsuo; Mika Mizuno; Beth Y Karlan; Ellen L Goode; Susanne K Kjær; Estrid Høgdall; Joellen M Schildkraut; Kathryn L Terry; Daniel W Cramer; Elisa V Bandera; Lisa E Paddock; Lambertus A Kiemeney; Leon F A G Massuger; Rebecca Sutphen; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Celeste L Pearce; Anna H Wu; Jolanta Kupryjanczyk; Allan Jensen; Penelope M Webb; Kirsten B Moysich; Australian Ovarian Cancer Study Group

doi:10.1158/1055-9965.EPI-17-0367

Back

History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium

Journal article

Open access

Peer reviewed

History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium

Albina N Minlikeeva, Jo L Freudenheim, Kevin H Eng, Rikki A Cannioto, Grace Friel, J Brian Szender, Brahm Segal, Kunle Odunsi, Paul Mayor, Brenda Diergaarde, …

Cancer epidemiology, biomarkers & prevention, Vol.26(9), pp.1470-1473

09/2017

DOI: https://doi.org/10.1158/1055-9965.EPI-17-0367

PMCID: PMC5649363

PMID: 28864456

Abstract

Comorbidity

Disease-Free Survival

Female

Humans

Ovarian Neoplasms - epidemiology

Ovarian Neoplasms - mortality

Survival Analysis

Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients. Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes. None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced). Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival. These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. .

Files and links (1)

url

https://doi.org/10.1158/1055-9965.EPI-17-0367View

Version of Record (VoR) Open

Metrics

10 Record Views

8 Times Cited - Web of Science

See more details

Details

Title: History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
Creators: Albina N Minlikeeva - Deparment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York
Jo L Freudenheim - Deparment of Epidemiology and Environmental Health, University at Buffalo, Buffalo, New York
Kevin H Eng - Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York
Rikki A Cannioto - Deparment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York
Grace Friel - Independent Health, Buffalo, New York
J Brian Szender - Department of Surgery, Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York
Brahm Segal - Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York
Kunle Odunsi - Center of Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York
Paul Mayor - Department of Surgery, Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York
Brenda Diergaarde - Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Emese Zsiros - Center of Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York
Linda E Kelemen - Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina
Martin Köbel - Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada
Helen Steed - Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Royal Alexandra Hospital, Edmonton, Alberta, Canada
Anna deFazio
Susan J Jordan - Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Peter A Fasching - Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany
Matthias W Beckmann - Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany
Harvey A Risch - Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut
Mary Anne Rossing - Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
Jennifer A Doherty - Department of Epidemiology, The Geisel School of Medicine at Dartmouth Medical, Hanover, New Hampshire
Jenny Chang-Claude - University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Marc T Goodman - Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
Thilo Dörk - Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Lower Saxony, Germany
Robert Edwards - Ovarian Cancer Center of Excellence, Women's Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Francesmary Modugno - Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania
Roberta B Ness - School of Public Health, The University of Texas, Houston, Texas
Keitaro Matsuo - Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan
Mika Mizuno - Department of Gynecological Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Beth Y Karlan - Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
Ellen L Goode - Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota
Susanne K Kjær - Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Estrid Høgdall - Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
Joellen M Schildkraut - Department of Public Health Sciences, School of Medicine, University of Virginia, Charlottesville, Virginia
Kathryn L Terry - Harvard T. H. Chan School of Public Health, Boston, Massachusetts
Daniel W Cramer - Harvard T. H. Chan School of Public Health, Boston, Massachusetts
Elisa V Bandera - Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Lisa E Paddock - School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey
Lambertus A Kiemeney - Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands
Leon F A G Massuger - Department of Gynaecology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
Rebecca Sutphen - Epidemiology Center, College of Medicine, University of South Florida, Tampa, Florida
Hoda Anton-Culver - Department of Epidemiology, University of California Irvine, Irvine, California
Argyrios Ziogas - Department of Epidemiology, University of California Irvine, Irvine, California
Usha Menon - Women's Cancer, Institute for Women's Health, University College London, London, United Kingdom
Simon A Gayther - Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California
Susan J Ramus - The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
Aleksandra Gentry-Maharaj - Women's Cancer, Institute for Women's Health, University College London, London, United Kingdom
Celeste L Pearce - Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California
Anna H Wu - Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California
Jolanta Kupryjanczyk - Deparment of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
Allan Jensen - Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
Penelope M Webb - Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Kirsten B Moysich - Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York
Australian Ovarian Cancer Study Group
Publication Details: Cancer epidemiology, biomarkers & prevention, Vol.26(9), pp.1470-1473
Date published: 09/2017
Grant note: R03 CA113148 / NCI NIH HHS N01 CN025403 / NCI NIH HHS R01 CA058860 / NCI NIH HHS P30 CA138313 / NCI NIH HHS UL1 TR001881 / NCATS NIH HHS K22 CA138563 / NCI NIH HHS R03 CA115195 / NCI NIH HHS R25 CA113951 / NCI NIH HHS P30 CA015083 / NCI NIH HHS K07 CA095666 / NCI NIH HHS R01 CA106414 / NCI NIH HHS T32 CA108456 / NCI NIH HHS R01 CA112523 / NCI NIH HHS R01 CA058598 / NCI NIH HHS P01 CA017054 / NCI NIH HHS P50 CA159981 / NCI NIH HHS R01 CA080742 / NCI NIH HHS P50 CA105009 / NCI NIH HHS UL1 TR000124 / NCATS NIH HHS R01 CA074850 / NCI NIH HHS R01 CA188900 / NCI NIH HHS N01 PC067010 / NCI NIH HHS R01 CA054419 / NCI NIH HHS K07 CA080668 / NCI NIH HHS R01 CA095023 / NCI NIH HHS R01 CA076016 / NCI NIH HHS R01 CA087538 / NCI NIH HHS P50 CA136393 / NCI NIH HHS R01 CA122443 / NCI NIH HHS R01 CA126841 / NCI NIH HHS P30 CA014089 / NCI NIH HHS K01 LM012100 / NLM NIH HHS P30 CA072720 / NCI NIH HHS
Academic Unit: Cancer Epidemiology and Health Outcomes
Language: English
Resource Type: Journal article
Identifiers: 991031665409604646